Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chronic Hepatitis C - Genotype 3”

155 trials

Showing 20 of 155 results

Large-scale testing (Phase 3)WithdrawnNCT01517308
What this trial is testing

24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C

Who this might be right for
Chronic Hepatitis C
Federico II University
Large-scale testing (Phase 3)Study completedNCT01854697
What this trial is testing

Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

Who this might be right for
Chronic Hepatitis C Infection
AbbVie 311
Large-scale testing (Phase 3)Study completedNCT03186313
What this trial is testing

Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection

Who this might be right for
Hepatitis C
Egyptian Liver Hospital 72
Large-scale testing (Phase 3)Study completedNCT01121705
What this trial is testing

Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)

Who this might be right for
Chronic Hepatitis
Casa Sollievo della Sofferenza IRCCS 360
Testing effectiveness (Phase 2)Study completedNCT01271790
What this trial is testing

Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Who this might be right for
Hepatitis C, Chronic
Gilead Sciences 245
Large-scale testing (Phase 3)Study completedNCT01616524
What this trial is testing

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Who this might be right for
Hepatitis C Virus (HCV)
Bristol-Myers Squibb 880
Large-scale testing (Phase 3)Study completedNCT02220998
What this trial is testing

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

Who this might be right for
Hepatitis C Virus Infection
Gilead Sciences 269
Large-scale testing (Phase 3)Study completedNCT00708500
What this trial is testing

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Who this might be right for
Hepatitis C, Chronic
Merck Sharp & Dohme LLC 404
Testing effectiveness (Phase 2)Study completedNCT01215643
What this trial is testing

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

Who this might be right for
Hepatitis CChronic Pain
Debiopharm International SA 340
Post-approval studies (Phase 4)Study completedNCT00553930
What this trial is testing

Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients

Who this might be right for
Hepatitis C, ChronicHIV Infections
Sociedad Andaluza de Enfermedades Infecciosas 71
Large-scale testing (Phase 3)Study completedNCT01701401
What this trial is testing

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Who this might be right for
Chronic Hepatitis C Virus
Gilead Sciences 870
Large-scale testing (Phase 3)Study completedNCT02032888
What this trial is testing

Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Who this might be right for
Hepatitis C
Bristol-Myers Squibb 238
Large-scale testing (Phase 3)Study completedNCT01573351
What this trial is testing

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Who this might be right for
Hepatitis C Virus
Bristol-Myers Squibb 398
Testing effectiveness (Phase 2)Study completedNCT01188772
What this trial is testing

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Who this might be right for
Hepatitis C Virus
Gilead Sciences 147
Large-scale testing (Phase 3)Study completedNCT02939989
What this trial is testing

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

Who this might be right for
Hepatitis C Virus Infection
AbbVie 33
Large-scale testing (Phase 3)Study completedNCT01753557
What this trial is testing

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Who this might be right for
Chronic Hepatitis C (CHC)
Tanabe Pharma Corporation 54
Not applicableEnded earlyNCT01100749
What this trial is testing

Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada

Who this might be right for
Chronic Hepatitis C - Genotype 3
University Health Network, Toronto 25
Large-scale testing (Phase 3)Study completedNCT03090035
What this trial is testing

Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment

Who this might be right for
Hepatitis CHepatitis C Relapse
Sheikh Zayed Medical College 98
Post-approval studies (Phase 4)Study completedNCT01841775
What this trial is testing

Interferon α 2b Pharmacovigilance Study

Who this might be right for
Hepatitis C, Chronic
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) 85
Large-scale testing (Phase 3)Study completedNCT02319031
What this trial is testing

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Who this might be right for
Hepatitis C
Bristol-Myers Squibb 53
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation